Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 5/20 | 0.95 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.95 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.95 |
| ▸ | OXTR | P30559 | 2/20 | 0.95 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vasopressin SCHEMBL17874853 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29688276 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.96 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL19733909 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL24390785 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL1172390 | 0.95 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739283-A1 | PEPTIDE STEREOCOMPLEXATION WITH BIODEGRADABLE STEREOREGULAR POLYESTERS IN WATER AND HYDROGEL FORMS THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2026-05-13 | — | — | EP | disclosed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4709357-A2 | EXTRACELLULAR VESICLE COMPOSITIONS AND PREPARATION | Virginia Tech Intellectual Properties, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12528852-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | Han, Jie (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| US-12257352-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-25 | — | — | US | disclosed |
| CN-112672763-B | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2025-03-25 | — | — | CN | disclosed |
| US-20250092111-A1 | POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION | UNIVERSITY OF WASHINGTON | 2025-03-20 | — | — | US | disclosed |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2024-05-09 | — | — | US | disclosed |
| US-11819578-B2 | Nanofiber scaffolds | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | disclosed |
| US-20230114205-A1 | NANOFIBER SCAFFOLDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023059870-A1 | NOVEL NANOFIBER SCAFFOLDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | disclosed |
| WO-2022081993-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | AVPR1A 4759/4885AVPR1B 4755/4885AVPR2 4856/4885 |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | AVPR1A 4759/4885AVPR1B 4755/4885AVPR2 4856/4885 |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | AVPR1A 1646/4885AVPR1B 992/4885AVPR2 1376/4885 |
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | CBR1, CBR3, SIGMAR1 | AVPR1A 1946/4885AVPR1B 1186/4885AVPR2 1805/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | AVPR1A 4440/4885AVPR1B 4481/4885AVPR2 4606/4885 |
| US-12528852-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | CBR1, CBR3, SIGMAR1 | AVPR1A 1662/4885AVPR1B 1716/4885AVPR2 1959/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | AVPR1A 4194/4885AVPR1B 3901/4885AVPR2 3546/4885 |
| US-20250092111-A1 | POTENT AND STABLE POLYPEPTIDE ANALOGUES VIA SERINE/THREONINE LIGATION | PTMS, DNPEP, TSSK6 | AVPR1A 1970/4885AVPR1B 2380/4885AVPR2 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.